Results 161 to 170 of about 1,322 (181)

T-Type Calcium Channels Are Inhibited by Fluoxetine and Its Metabolite Norfluoxetine

Molecular Pharmacology, 2006
Fluoxetine, a widely used antidepressant that primarily acts as a selective serotonin reuptake inhibitor, also inhibits various neuronal ion channels. Using the whole-cell patch-clamp technique, we have examined the effects of fluoxetine and norfluoxetine, its major active metabolite, on cloned low-voltage-activated T-type calcium channels (T channels)
Achraf, Traboulsie, Jean, Chemin, Elodie, Kupfer, Joël, Nargeot, Philippe, Lory   +4 more
openaire   +2 more sources

Determination of Fluoxetine and Norfluoxetine in Human Plasma by Ion-Interaction RP-HPLC

Journal of Liquid Chromatography & Related Technologies, 1997
Abstract The paper reports a sensitive Ion-Interaction Reverse Phase HPLC-UV method for the separation and determination of fluoxetine ((±)N-methyl-(4-(trifluoromethyl)phenoxy) benzene-propanamine) in human plasma. An ODS silica-based column is used as the stationary phase and the mobile phase consists of 5.00 mM octylamine in water/acetonitrile (60/40
GENNARO M.C., ABRIGO C., ANGELINO S., ALBERT U., BOGETTO F., G. MAINA, PROLO P., RAVIZZA L.   +7 more
openaire   +2 more sources

Red cell and plasma concentrations of fluoxetine and norfluoxetine.

Veterinary and human toxicology, 1993
To study the distribution of fluoxetine and norfluoxetine in blood compartments we determined their concentrations in red cells and plasma after the addition of 500 ng/ml of each compound to human blood in vitro. Red cell and plasma fluoxetine concentrations were 493 +/- 79 ng/ml and 454 +/- 53 ng/ml, respectively (P > 0.1).
Y, Amitai, E, Kennedy, P, DeSandre, J, Fawcett, H, Frischer   +4 more
openaire   +1 more source

Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation.

The Journal of clinical psychiatry, 1992
Sedation is an often unanticipated but clinically significant side effect in some patients treated with fluoxetine. To date, no clinical or pharmacokinetic factors have been identified in association with sedation in fluoxetine-treated patients. We hypothesized that patients experiencing sedation might have elevated plasma concentrations of fluoxetine ...
P E, Keck, S L, McElroy
openaire   +1 more source

The in vitro estrogenic activity of fluoxetine and norfluoxetine

Toxicology Letters, 2015
D. Lupu, A. Pop, J. Cherfan, B. Kiss, F. Loghin   +4 more
openaire   +1 more source

Fluoxetine and Norfluoxetine

American Journal of Psychiatry, 1998
openaire   +2 more sources

Fluoxetine and norfluoxetine plasma levels in major depression

Biological Psychiatry, 1995
J.D. Amsterdam, M. Hornig-Rohan, J.F. Rosenbaum, F.M. Quitkin, J. Fawcette, F.W. Reimherr, C.M. Beasley   +6 more
openaire   +1 more source

Fluoxetine and Norfluoxetine Plasma Levels After Discontinuing Fluoxetine Therapy

Journal of Clinical Psychopharmacology, 2001
D J, Brunswick, J D, Amsterdam, J, Fawcett, F M, Quitkin, F W, Reimherr, J F, Rosenbaum, C M, Beasley   +6 more
openaire   +2 more sources

ANTIDEPRESSANT RESPONSE AND PLASMATIC LEVELS TO FLUOXETINE AND NORFLUOXETINE

Clinical Neuropharmacology, 1992
V. Perez-Sola, J. Perez-Blanco, E. Alvarez, J. M. Queralto, J. Soriano, M. Dolera, C. Mariscot   +6 more
openaire   +1 more source

A practical asymmetric synthesis of (R)-fluoxetine and its major metabolite (R)-norfluoxetine

Tetrahedron Letters, 2001
Chris H Senanayake
exaly